Login
$ERAS
$15.11 +$0.00 (0.0%) After hours

$ERAS 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition
16 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by the Chief...

24 Aug 2026 8-K: Other Events

On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.

11 Aug 2026 8-K: Results of Operations and Financial Condition

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination

10 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. (“the Company”).

14 Jul 2026 8-K: Other Events

31,428,572 Shares of Common Stock, par value $0.0001 per share

13 Jul 2026 8-K: Other Events

On July 13, 2026, Erasca, Inc. (the “Company”) announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Updated preliminary data from the Com...

01 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2026, Erasca, Inc. (the Company) held its annual meeting of stockholders (the Annual Meeting). As of the close of business on April 27, 2026, the record date for the Annual Meeting, there were 310,965,971 shares of common sto...

11 May 2026 8-K: Results of Operations and Financial Condition

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents

27 Apr 2026 8-K: Other Events

On April 27, 2026, Erasca, Inc. (the “Company”) announced positive preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

27 Apr 2026 8-K: Regulation FD Disclosure; Other Events

On April 27, 2026, Erasca, Inc. (the “Company”) announced that it will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients ...

21 Apr 2026 8-K: Other Events

On April 21, 2026, Erasca, Inc. (the “Company”) narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no lat...

12 Mar 2026 8-K: Results of Operations and Financial Condition

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics

29 Jan 2026 8-K: Other Events

On January 20, 2026, Erasca, Inc. (the “Company”) disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million. On January 23, 2026, the Company announced th...

22 Jan 2026 8-K: Other Events

22,500,000 Shares of Common Stock, par value $0.0001 per share

20 Jan 2026 8-K: Results of Operations and Financial Condition

Erasca, Inc. (the “Company”) is providing the following financial information. As of December 31, 2025, our cash, cash equivalents and marketable securities were approximately $341.8 million.

12 Jan 2026 8-K: Regulation FD Disclosure; Other Events

On a Journey to Erase Cancer Erasca Corporate Presentation January 2026 Eric and his wife Margaret, inspiring our bold mission to erase cancer Exhibit 99.1

12 Nov 2025 8-K: Results of Operations and Financial Condition

U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015

12 Aug 2025 8-K: Results of Operations and Financial Condition

Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001

26 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 24, 2025, Erasca, Inc. (the Company) held its annual meeting of stockholders (the Annual Meeting). As of the close of business on April 28, 2025, the record date for the Annual Meeting, there were 283,287,382 shares of common sto...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support